Secukinumab

Introduction Overview

Generic Name

secukinumab

Brand Name

Cosentyx

Dosage Form

Sensoready pen, prefilled syringes, single-dose vial, intravenous infusion

Drug Class

Interleukin inhibitors

Pharmacokinetics

Absorption: Secukinumab, the active monoclonal antibody in Cosentyx, is administered primarily via subcutaneous injection or intravenous infusion. After subcutaneous administration, secukinumab exhibits slow absorption with a mean time to maximum serum concentration (Tmax) of approximately 5 to 6 days. The bioavailability following subcutaneous injection is approximately 55–77%. Intravenous administration results in direct systemic availability with peak concentrations achieved at the end of infusion. Factors such as injection site and patient characteristics may influence absorption rates, but no clinically significant variations have been observed.

Distribution: Secukinumab distributes primarily into the vascular and interstitial spaces. The mean volume of distribution is approximately 7.1 liters, consistent with distribution mainly in extracellular fluid. Being a large monoclonal antibody, secukinumab does not readily cross cell membranes or the blood-brain barrier. Binding to interleukin-17A is highly specific, and distribution to target tissues affected by autoimmune inflammation enables therapeutic efficacy.

Metabolism: Secukinumab, as a fully human IgG1-kappa monoclonal antibody, undergoes catabolism similar to endogenous IgG antibodies. It is metabolized via proteolytic degradation into small peptides and amino acids by lysosomal enzymes in reticuloendothelial cells. This process is non-saturable and does not involve cytochrome P450 enzymes, therefore it has a low potential for metabolic drug-drug interactions. The rate of metabolism can be influenced by factors like immunogenicity and systemic inflammation.

Elimination: The mean elimination half-life of secukinumab is approximately 27 days, supporting the monthly dosing schedule after loading. Clearance of secukinumab is slow due to its large molecular size and specific catabolic degradation pathways. No renal or hepatic excretion occurs as intact antibody. The half-life may vary slightly depending on patient factors or concomitant illnesses, but no significant accumulation has been observed during chronic administration.

Dosage Forms

Available Dosage Forms:
- Cosentyx Sensoready pen: 150 mg/mL single-dose injection.
- Cosentyx UnoReady pen and single-dose prefilled syringe: 300 mg/2 mL injection.
- Cosentyx prefilled syringe for pediatric patients <50 kg: 75 mg/0.5 mL.
- Cosentyx prefilled syringe: 150 mg/mL (single-dose).
- Cosentyx single-dose vial for intravenous infusion: 125 mg/5 mL.
(Note: The 300 mg/2 mL prefilled syringe and 150 mg single-dose vial have been discontinued.)

Dosages for Adults and Adolescents:
- Plaque Psoriasis (adults): 300 mg subcutaneously at weeks 0, 1, 2, 3, and 4, then every 4 weeks. Administered as two 150 mg injections; 150 mg dose may be acceptable in some cases.
- Plaque Psoriasis (pediatrics ≥6 years): Weight-based dosing; <50 kg: 75 mg, ≥50 kg: 150 mg by subcutaneous injection at weeks 0, 1, 2, 3, and 4, then every 4 weeks.
- Psoriatic Arthritis (adults): 150 mg subcutaneously at weeks 0, 1, 2, 3, and 4, then every 4 weeks. Dose may increase to 300 mg if active disease persists. Can be administered with or without methotrexate.
- Psoriatic Arthritis (pediatrics ≥2 years): Weight-based as 75 mg for 15–<50 kg, 150 mg for ≥50 kg following the same loading and maintenance schedule.
- Ankylosing Spondylitis (adults): 150 mg subcutaneously weekly at weeks 0–4 then every 4 weeks; 300 mg every 4 weeks can be considered if disease remains active.
- Non-Radiographic Axial Spondyloarthritis (adults): 150 mg subcutaneously weekly at weeks 0–4 then every 4 weeks.
- Enthesitis-Related Arthritis (patients ≥4 years): Weight-based dosing identical to psoriatic arthritis pediatric dosing.
- Hidradenitis Suppurativa (adults): 300 mg subcutaneously weekly at weeks 0–4, then every 4 weeks. Dose may increase to every 2 weeks if response is inadequate.

Specific Patient Populations:
- Pediatric patients with body weight below thresholds receive proportionally adjusted dosing.
- Self-administration is approved for adults and pediatric patients with caregiver assistance for younger children.
- Intravenous dosing for PsA, AS, and nr-axSpA: 6 mg/kg loading dose at week 0 followed by 1.75 mg/kg every 4 weeks; max 300 mg per infusion.
- Dose adjustments based on therapeutic response are suggested for certain indications.
- No adjustments are specified for mild-to-moderate hepatic or renal impairment due to monoclonal antibody metabolism.

Mechanism Of Action

Cosentyx (secukinumab) is a human monoclonal IgG1-kappa antibody that selectively binds to and neutralizes interleukin-17A (IL-17A), a pro-inflammatory cytokine prominently involved in the pathogenesis of several autoimmune and inflammatory diseases. IL-17A is produced mainly by Th17 cells and acts by binding to IL-17 receptors on various cell types, inducing the release of inflammatory mediators, chemokines, and cytokines that promote tissue inflammation and damage.

By blocking IL-17A, secukinumab interrupts the signaling cascade that would otherwise activate keratinocytes in plaque psoriasis, synovial fibroblasts in psoriatic arthritis, and entheseal sites in ankylosing spondylitis and related conditions. This downstream inhibition results in the decreased recruitment of neutrophils and other inflammatory cells, reduction of inflammatory cytokine expression (e.g., TNF-α, IL-6), and diminished amplification of chronic inflammatory responses.

Cellularly, secukinumab prevents IL-17A from binding to its receptor complex, which includes IL-17RA and IL-17RC subunits. This blockade inhibits the activation of intracellular adaptor proteins, nuclear factor-kappa B (NFκB) pathway, and mitogen-activated protein kinases (MAPKs), all of which mediate pro-inflammatory gene transcription. The net effect is a marked attenuation of inflammation, tissue remodeling, and symptom severity.

Clinically, suppression of IL-17A has demonstrated robust efficacy in improving dermatological lesions, joint symptoms, and systemic inflammation across multiple autoimmune diseases. Comparative studies with other biologics targeting tumor necrosis factor or IL-23 suggest that IL-17A blockade provides a distinct and effective mechanism. Research continues to investigate IL-17A's complex role in immunity and how selective inhibition by secukinumab balances efficacy with infection risk, given IL-17A's involvement in mucocutaneous defense mechanisms.

Pharmacological Actions

Selective inhibition of interleukin-17A (IL-17A), a key cytokine in autoimmune inflammation.
Suppression of inflammatory cytokine production including TNF-α, IL-6, and IL-1β.
Reduction of neutrophil recruitment and activation at sites of inflammation.
Blockade of IL-17A receptor signaling pathways (NFκB and MAPK inhibition).
Alleviation of keratinocyte hyperproliferation in plaque psoriasis.
Modulation of synovial inflammation in psoriatic arthritis and ankylosing spondylitis.
Improvement of enthesitis and axial inflammation associated with spondyloarthritis.
Dampening of inflammatory cell migration and tissue damage.
Reduction in skin plaque formation and psoriatic lesion severity.
Potential restoration of immune homeostasis in autoimmune conditions.
Does not significantly interfere with other interleukin or tumor necrosis factor pathways.
Exhibits immunomodulatory effects without broad immunosuppression.

Therapeutic Or Clinical Uses

Treatment of moderate to severe plaque psoriasis in adults and pediatric patients 6 years and older.
Management of active psoriatic arthritis in patients aged 2 years and above.
Therapy for active ankylosing spondylitis in adult patients.
Treatment of active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation in adults.
Treatment of active enthesitis-related arthritis (ERA) in patients 4 years and older.
Management of moderate to severe hidradenitis suppurativa (HS) in adult patients.
Used for patients who are candidates for systemic therapy or phototherapy in plaque psoriasis.
Monotherapy or concomitant therapy with methotrexate in psoriatic arthritis.
Intravenous infusion option available for certain autoimmune conditions requiring healthcare administration.
Off-label exploration in other IL-17 mediated inflammatory disorders (ongoing research).
Improves symptoms such as inflammation, pain, and skin lesion clearance.
Can be used when patients have inadequate response or intolerance to other systemic therapies.

Side Or Adverse Effects

Diarrhea, frequently mild in severity.
Upper respiratory tract symptoms such as nasal congestion, sneezing, and sore throat.
Injection site reactions including redness, itching, or pain.
Increased susceptibility to infections including bacterial, viral, and fungal opportunistic infections.
Potential reactivation of latent infections, notably hepatitis B virus.
Hypersensitivity or allergic reactions including hives, chest tightness, and anaphylaxis.
Rare cases of inflammatory bowel disease exacerbation or new onset.
Musculoskeletal pain and muscle aches.
Headache and fatigue reported in some patients.
Possible occurrence of cold symptoms such as cough and sore throat.
Potential development of antibody formation against the drug (immunogenicity).
Gastrointestinal symptoms including abdominal pain or discomfort.
Weight changes reported anecdotally but not established as common.
Rare severe infections including tuberculosis reactivation.
Possible hematologic abnormalities such as neutropenia or leukopenia (uncommon).

Precautions

Evaluate patients for active or chronic infections prior to initiation of therapy.
Screen for tuberculosis before administration and monitor for signs of infection during treatment.
Use cautiously in patients with a history of inflammatory bowel disease.
Avoid live vaccines concurrently; ensure vaccination status is updated prior to therapy.
Advise patients on increased risk of infections and instruct to report symptoms promptly.
Monitor patients for allergic or hypersensitivity reactions during and after injections.
Advise patients with latex allergies to avoid handling needle caps of Sensoready pen and prefilled syringes.
Use caution in populations with potential impaired immune responses, such as the elderly or immunocompromised.
Assess pregnancy status and weigh risks versus benefits; limited data on use during pregnancy.
Consider potential effects on breastfeeding; safety during lactation is unknown.
Instruct patients on proper storage and handling to maintain drug stability and efficacy.
Be aware of possible increased infection risk with concomitant immunosuppressive therapies.
Avoid abrupt discontinuation without consulting healthcare provider due to risk of disease flare.
Educate patients regarding signs of infection, allergic reaction, or gastrointestinal symptoms.
Regularly evaluate clinical response to adjust dosage or discontinue therapy if necessary.

Warnings

Cosentyx lowers immune system activity, increasing susceptibility to serious infections.
Do not initiate therapy in patients with active infections until they are adequately treated.
Monitor closely for signs of infection such as fever, chills, cough, painful urination, or skin sores.
Cases of tuberculosis and hepatitis B reactivation have been reported during treatment.
Patients should be informed about the risk of allergic reactions potentially leading to anaphylaxis.
Use is contraindicated in patients with known hypersensitivity to secukinumab or its components.
Avoid live vaccines during treatment and for an adequate period afterward.
Use caution in patients with pre-existing inflammatory bowel disease, as exacerbations have occurred.
Pregnancy safety has not been established; potential fetal risk cannot be ruled out.
Immunogenicity may lead to reduced efficacy or increased adverse reactions.
Potential increased risk for malignancies has not been fully established; monitor long-term safety.
Patients should not share Cosentyx pens or syringes to prevent cross-contamination.
In the event of infection or serious adverse event, delay further doses until resolution.
Not recommended for pediatric patients under specified age or weight limits due to lack of safety data.
Advise patients regarding appropriate disposal of used needles and syringes.

Contraindication

Known hypersensitivity to secukinumab or any of the inactive ingredients in Cosentyx formulations.
Patients with active, severe infections should not receive Cosentyx until infections resolve.
Individuals with latex allergy should avoid handling needle caps of Sensoready pens or prefilled syringes containing latex components.
Use is contraindicated in combination with live vaccines.
Not recommended for patients under 2 years old or under 15 kg for psoriatic arthritis indications due to lack of safety data.
Patients with history of severe allergic reactions to monoclonal antibodies should avoid use.
Concurrent use with other biologics that modulate the immune system may be contraindicated.
Discontinuation in suspected hypersensitivity or anaphylactic reactions is mandatory.
Not approved for treatment of acute infections or immunodeficiency states.

Drug Interactions

No direct pharmacokinetic drug interactions due to catabolism pathway distinct from cytochrome P450 enzymes.
May interact indirectly with CYP450 substrates due to modulation of inflammatory pathways; monitoring advised for narrow therapeutic index drugs.
Concomitant use with other immunosuppressants or biologics may increase risk of infection.
Live vaccines should not be administered concurrently due to immunosuppressive effects.
Avoid administering Cosentyx with other IL-17 inhibitors or other biologics targeting similar pathways to reduce overlapping immunosuppression.
Potential interaction with methotrexate is clinically accommodated; Cosentyx can be used with or without methotrexate.
Monitoring recommended when combined with drugs highly dependent on CYP450 enzymes due to possible cytokine-mediated alteration of enzyme activity.
No significant interactions with common over-the-counter medications have been observed.
Concomitant corticosteroid therapy may increase risk of infection; use caution.
No known interactions with antihypertensives or lipid-lowering agents directly documented.
Patients should inform healthcare providers about all medications including herbal supplements to identify potential unidentified interactions.
No specific interactions with COVID-19 vaccines; non-live vaccines can be administered safely.
Avoid simultaneous administration with other experimental immunomodulators without clinical guidance.

Preparations Of The Drug

Cosentyx Sensoready pen: Prefilled single-dose injection containing 150 mg/mL secukinumab for subcutaneous use.
Cosentyx UnoReady pen: Prefilled single-dose injection containing 300 mg/2 mL secukinumab for subcutaneous use (delivers higher dose in one injection).
Cosentyx prefilled syringe for pediatric patients: 75 mg/0.5 mL single-dose syringe for subcutaneous injection.
Cosentyx prefilled syringe: 150 mg/mL single-dose syringes for subcutaneous administration.
Cosentyx single-dose vial: 125 mg/5 mL for intravenous infusion administered by healthcare professionals (requires dilution and slow infusion over 30 minutes).
Inactive ingredients include L-histidine/histidine hydrochloride monohydrate, L-methionine, polysorbate 80, trehalose dihydrate, sucrose, and sterile water for injection depending on formulation.
Needle caps on Sensoready pen and certain prefilled syringes contain latex; contraindicated in latex-sensitive individuals.
Storage in refrigerator (2ºC to 8ºC); may be kept at room temperature up to 86ºF (30ºC) for up to 4 days prior to administration.
Do not freeze or shake; maintain original carton to protect from light until use.
Dispose of all used pens, syringes, and needles in appropriate sharps containers per local regulations.
Cosentyx is supplied in single-dose presentations; no multi-dose vials are marketed.
Packages include detailed instructions for subcutaneous injection technique for patients and caregivers.
Intravenous formulation requires aseptic preparation and administration by trained healthcare personnel.
Prefilled syringes and pens have visual indicators confirming dose delivery for patient reassurance.
Cosentyx is manufactured by Novartis Pharmaceuticals Corporation.